GlioME Team: another new paper in Cell Death & Disease!
A new article from the GlioME Team has just been published in Cell Death and Disease: SMAC mimetic drives microglia phenotype and glioblastoma immune microenvironment.
The PFNT Facility is a coherent set of exploration tools in neurobiology allowing research at the molecular, cellular and integrated levels.
Because generation of patient avatar for preclinical therapeutic development is critically needed in neuro-oncology, the GlioME team in collaboration with the PETRA"TECH" platform developed an easy method to generate tumoroids from primary and metastatic brain tumors, including a dedicated 3D spatial analysis workflow for drug development.
Three presentations at the ESMO Congress 2024 (Barcelona, 13–17 September) reported on therapies designed to stimulate or boost the body’s antitumour immune response in the management of aggressive, high-grade gliomas, which typically carry a poor prognosis.
Emeline Tabouret from GlioME Team discussed these data during the proffered paper session – CNS tumours reported here.
Maud, Chiara, and Matthew (SynapTau team) are happy to announce the award of an ERC Starting Grant for the team, with the project set to begin in January 2025. The ERC project "SynApoE" aims to characterize how ApoE4 controls synaptic degeneration in Alzheimer's disease.
We invite you to celebrate this great news on September 23rd, during Maud's HDR celebration.
We look forward to sharing this moment with you!
We’re over the moon to see our latest work with Stéphane Vassilopoulos and his team published in Science. Check out how we reveal the unique architecture of clathrin-coated pits and endocytosis at the axon initial segment!
Comme chaque année les équipes 8, 9 et 10 de l’INP ont participé au Séminaire Annuel du Canceropôle qui se tenait au Palais des Congrès de Saint-Raphaël les 4 et 5 juillet 2024.
Congratulations to Chiara Bordier (team 2 SynapTau) for receiving the GBM (Association for Biochemistry and Molecular Biology) Master Prize for the best master’s thesis! This year, Professor Lichtenthaler from Technische Universität München and the DZNE presented this honour, marking the fourth time it has been awarded. Chiara's award-winning research explored the impact of Tau protein on nuclear organization and chromatin dynamics in neurodegenerative diseases, highlighting its crucial role in nuclear tension and stress response.
INP and Vect-Horus both participated to the symposium “Imagining the future of cancer treatments” (~100 participants) organized by the Translate-It departement of CRCM in Luminy. Along with keynote speaker Maria Kavallaris (Director of the Australian Centre for NanoMedicine at UNSW), François Devred gave an overview of INP's work on cancer entitle "How the INP contributes to the future of cancer treatments" and Pavlo Shpak-Kraievskyi of Vect-Horus gave a talk on "Surface modification of LNPs for brain targeting of nucleic acids".
Sofia (PhD student team 7), Charbel (PhD student teams 3 and 9) and Jehanne (PhD student team 5) attended and presented posters at FENS 2024 in Vienna (Austria). It was an enriching experience to discuss their work with their peers, attend presentations on innovative research in our respective fields, and enjoy typical Austrian dishes with other members of NeuroMarseille and beyond.
A new article from the GlioME Team has just been published in Cell Death and Disease: SMAC mimetic drives microglia phenotype and glioblastoma immune microenvironment.
Because generation of patient avatar for preclinical therapeutic development is critically needed in neuro-oncology, the GlioME team in collaboration with the PETRA"TECH" platform developed an easy method to generate tumoroids from primary and metastatic brain tumors, including a dedicated 3D spatial analysis workflow for drug development.
Three presentations at the ESMO Congress 2024 (Barcelona, 13–17 September) reported on therapies designed to stimulate or boost the body’s antitumour immune response in the management of aggressive, high-grade gliomas, which typically carry a poor prognosis.
Emeline Tabouret from GlioME Team discussed these data during the proffered paper session – CNS tumours reported here.
The NeuroCyto lab is looking to hire a postdoctoral fellow for an exciting project on novel mechanisms of microtubule turnover in neurons, in collaboration with collaboration with the lab of Manuel Théry and Laurent Blanchoin (CytoMorpho lab, ESPCI, Paris).
Maud, Chiara, and Matthew (SynapTau team) are happy to announce the award of an ERC Starting Grant for the team, with the project set to begin in January 2025. The ERC project "SynApoE" aims to characterize how ApoE4 controls synaptic degeneration in Alzheimer's disease.
We invite you to celebrate this great news on September 23rd, during Maud's HDR celebration.
We look forward to sharing this moment with you!
We’re over the moon to see our latest work with Stéphane Vassilopoulos and his team published in Science. Check out how we reveal the unique architecture of clathrin-coated pits and endocytosis at the axon initial segment!
Congratulations to Chiara Bordier (team 2 SynapTau) for receiving the GBM (Association for Biochemistry and Molecular Biology) Master Prize for the best master’s thesis! This year, Professor Lichtenthaler from Technische Universität München and the DZNE presented this honour, marking the fourth time it has been awarded. Chiara's award-winning research explored the impact of Tau protein on nuclear organization and chromatin dynamics in neurodegenerative diseases, highlighting its crucial role in nuclear tension and stress response.